Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The risk for developing cancer in Israeli ATM, BLM, and FANCC heterozygous mutation carriers.

Cancer genetics - 1 Mar 2016

Laitman Yael, Boker-Keinan Lital, Berkenstadt Michal, Liphsitz Irena, Weissglas-Volkov Daphna, Ries-Levavi Liat, Sarouk Ifat, Pras Elon, Friedman Eitan

Abstract excerpt

Cancer risks in heterozygous mutation carriers of the ATM, BLM, and FANCC genes are controversial. To shed light on this issue, cancer rates were evaluated by cross referencing asymptomatic Israeli heterozygous mutation carriers in the ATM, BLM, and FANCC genes with cancer diagnoses registered at the Israeli National Cancer Registry (INCR). Comparison of observed to expected Standardized Incidence Rates (SIR) was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ataxia Telangiectasia Mutated Proteins
Share to Genetic Predisposition to Disease

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Heterozygote

Share to Mutation

Share to Neoplasms

Share to RecQ Helicases

Share to Young Adult

Source

Identifiers

PMID: 26778106
DOI: 10.1016/j.cancergen.2015.12.006

Genes

ATM
BLM
FANCC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The risk for developing cancer in Israeli ATM, BLM, and FANCC heterozygous mutation carriers.PMID 26778106Read ↗

Mutational analysis of candidate genes in Israeli male breast cancer cases.Semantic proximity Read ↗

Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999.Semantic proximity Read ↗

Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.Semantic proximity Read ↗

ATM haplotypes and breast cancer risk in Jewish high-risk women.Semantic proximity Read ↗

Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers.Semantic proximity Read ↗

CHEK2*1100delC and male breast cancer risk in IsraelSemantic proximity Read ↗

Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2.Semantic proximity Read ↗

Colorectal and Endometrial Cancer Risk and Age at Diagnosis in BLMAsh Mutation Carriers.Semantic proximity Read ↗

Breast cancer risk prediction accuracy in Jewish Israeli high-risk women using the BOADICEA and IBIS risk models.Semantic proximity Read ↗

Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers.Semantic proximity Read ↗

The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.